A nationwide study of multimedicine use in people treated with cardiovascular medicines in Australia.
- Published in:
- Pharmacotherapy, 2022, v. 42, n. 11, p. 828, doi. 10.1002/phar.2735
- By:
- Publication type:
- Article
Works matching IS 02770008 AND DT 2022 AND VI 42 AND IP 11
Results: 6
1
2
Path of least recurrence: A systematic review and meta‐analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection.
- Published in:
- Pharmacotherapy, 2022, v. 42, n. 11, p. 810, doi. 10.1002/phar.2734
- By:
- Publication type:
- Article
3
Prophylaxis for Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease: A systematic review.
- Published in:
- Pharmacotherapy, 2022, v. 42, n. 11, p. 858, doi. 10.1002/phar.2733
- By:
- Publication type:
- Article
4
Gut microbiome health and dysbiosis: A clinical primer.
- Published in:
- Pharmacotherapy, 2022, v. 42, n. 11, p. 849, doi. 10.1002/phar.2731
- By:
- Publication type:
- Article
5
Evaluating the evidence for sacubitril/valsartan across the continuum of heart failure.
- Published in:
- Pharmacotherapy, 2022, v. 42, n. 11, p. 837, doi. 10.1002/phar.2730
- By:
- Publication type:
- Article
6
Issue Information.
- Published in:
- Pharmacotherapy, 2022, v. 42, n. 11, p. 807, doi. 10.1002/phar.2425
- Publication type:
- Article